Global Age Related Macular Degeneration Market Expected to Surpass $16.2 Billion by 2033 The global age-related macular degeneration market is projected to reach $16.2 billion by 2033, driven by rising cases and aging populations.

Global Age Related Macular Degeneration Market Expected to Surpass $16.2 Billion by 2033 #None #Wet_AMD #Aflibercept #Age_Related_Macular_Degeneration

リジェネロン、アフリベルセプト8mgのRVO第3相最終64週結果など発表へ──ELARA試験で月1回投与の主要結果も提示予定 | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見

リジェネロン、アフリベルセプト8mgのRVO第3相最終64週結果など発表へ──ELARA試験で月1回投与の主要結果も提示予定
Regeneron to Present Final 64-Week Phase 3 QUASAR Results in RVO and Primary Data from Monthly Dosing ELARA Trial of Aflibercept 8 mg

stellanews.life/technology/8...

#RetinalDisease
#Aflibercept
#ClinicalTrials

PULSAR supports aflibercept 8 mg as alternative monotherapy for PCV Aflibercept 8 mg every 12 or 16 weeks offers similar visual and anatomic outcomes to aflibercept 2 mg every 8 weeks in people with polypoidal choroidal vasculopathy.

#MedNews - Aflibercept 8 mg every 12 or 16 weeks offers similar visual and anatomic outcomes to #aflibercept 2 mg every 8 weeks in people with polypoidal choroidal #vasculopathy.

👉 buff.ly/1J9l1WB

#EyeSky

#MedNews - Real-world data suggest a higher incidence of intraocular inflammation after intravitreal injection of #aflibercept 8 mg than has been previously reported in clinical trials.

👉 buff.ly/tCn0lVC

#EyeMed #MacularDegeneration

Regeneron Moves to Strike and Dismiss Amgen’s Counterclaims in Aflibercept Litigation On November 12, 2025, Regeneron filed a Motion to Strike Certain Affirmative Defenses and Dismiss Certain Counterclaims against Amgen in the aflibercept patent litigation in the U.S. District Court fo...

Regeneron Moves to Strike and Dismiss Amgen’s Counterclaims in Aflibercept Litigation

#Litigation #Aflibercept #BigMoleculeWatch

www.bigmoleculewatch.com/2025/11/18/r...

#UvealMelanoma cells with a GNA11Q209L or GNAQQ209L mutation secrete #VEGF to induce #EndothelialPermeability, facilitating UM cell transmigration across the endothelium, while systemic #Aflibercept & KAI treatment inhibit circulating UM cells.

#OpenAccess: doi.org/10.1038/s413...

Retinal Vein Occlusion Subtypes Can Be Treated With High Dose Aflibercept - Ophthalmology Advisor Researchers compared the use of aflibercept 8 mg and 2 mg in patients with various retinal vein occlusion subtypes.

#AAO2025: Treatment with high dose #Aflibercept 8 mg can lead to similar #VisualOutcomes with fewer injections for patients with various #RetinalVeinOcclusion (RVO) subtypes.

Read more: https://bit.ly/4o3qTSp

#Ophthalmology #EyeSky #RVO #MedSky

Aflibercept offers sustained nAMD control at extended dosing intervals Aflibercept provides sustained visual acuity for up to 2 years in patients with neovascular age-related macular degeneration when given at a dose of 8 mg every 12 or 16 weeks.

#MedNews - #Aflibercept provides sustained visual acuity for up to 2 years in patients with #nAMD when given at a dose of 8 mg every 12 or 16 weeks.

Full story 👉https://buff.ly/o2TNBm9

#EyeSky

Maculopatie, nuove conferme su efficacia anti-Vegf a intervalli fino a 6 mesi (Adnkronos) - Sono stati presentati alla 25esima edizione del Congresso Euretina, in corso a Parigi fino al 7 settembre, importanti aggiornamenti su aflibercept 8 mg, con dati real world, che confermano la sua efficacia terapeutica per ...

TI POTREBBE INTERESSARE: Maculopatie, nuove conferme su efficacia anti-Vegf a intervalli fino a 6 mesi ... LEGGI TUTTO #maculopatie #aflibercept #antiVEGF #terapia #congresso

Maculopatie, nuove conferme su efficacia anti-Vegf a intervalli fino a 6 mesi (Adnkronos) - Sono stati presentati alla 25esima edizione del Congresso Euretina, in corso a Parigi fino al 7 settembre, importanti aggiornamenti su aflibercept 8 mg, con dati real world, che confermano la sua efficacia terapeutica per ...

È ACCADUTO IERI: Maculopatie, nuove conferme su efficacia anti-Vegf a intervalli fino a 6 mesi ... LEGGI TUTTO #Maculopatie #Euretina2023 #Aflibercept #SaluteOculare #RicercaClinica

Maculopatie, nuove conferme su efficacia anti-Vegf a intervalli fino a 6 mesi (Adnkronos) - Sono stati presentati alla 25esima edizione del Congresso Euretina, in corso a Parigi fino al 7 settembre, importanti aggiornamenti su aflibercept 8 mg, con dati real world, che confermano la sua efficacia terapeutica per ...

Maculopatie, nuove conferme su efficacia anti-Vegf a intervalli fino a 6 mesi ... LEGGI TUTTO #maculopatia #aflibercept #terapia #salute #occhi

Stada revives talk of an IPO – if conditions improve Germany's Stada has said it may make another attempt to seek a public listing in the autumn, after delaying its plans earlier this year.

#Stada #IPO #pharmaindustry #generics #OTC #specialtymedicines #rarediseases #chronicdiseases #biosimilars #plaquepsoriasis #psoriaticarthritis #Crohnsdisease #specialtybiosimilars #aflibercept #denosumab #golimumab #tocilizumab #blockbusterdrugs #GLP1agonists #diabetes #obesity
zurl.co/nbsw4

#UvealMelanoma cells with GNA11/GNAQ mutations secrete VEGF, which promotes UM cell transmigration. Systemic #Aflibercept & KAI treatments hold promising potential against UM metastasis. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

Alteogen’s Aflibercept Biosimilar Receives Positive CHMP Opinion We previously reported that South Korean biopharmaceutical company Alteogen submitted its Marketing Authorization Application to the European Medicines Agency (“EMA”) for ALT-L9, what has since been n...

Alteogen’s Aflibercept Biosimilar Receives Positive CHMP Opinion

#Biosimilar #Aflibercept #BigMoleculeWatch

www.bigmoleculewatch.com/2025/08/22/a...

4DMT's stock climbs as eye disease gene therapy patients keep jettisoning injections 4D Molecular Therapeutics has posted 60-week | 4D Molecular Therapeutics has posted 60-week data on a gene therapy, providing evidence of durability in diabetic macular edema and sending its stock up…

Gene therapy delivering anti-VEGF shows promise in treating DME, offering hope to patients tired of regular IVT injections. Despite challenges in the gene therapy field, the ocular domain proves safe for this technology. #genetherapy #CNV #DME #aflibercept
buff.ly/b0gFsak

Alteogen's Aflibercept Biosimilar EYLUXVI® Receives Positive CHMP Opinion Alteogen's EYLUXVI®, an aflibercept biosimilar, receives a positive opinion from CHMP, paving the way for improved treatment of age-related macular degeneration.

Alteogen's Aflibercept Biosimilar EYLUXVI® Receives Positive CHMP Opinion #South_Korea #Daejeon #Aflibercept #EYLUXVI #Alteogen

Boehringer raises hope of oral drug for diabetic eye disease Boehringer has started a phase 2 trial of an oral therapy that could help people with diabetic macular oedema avoid regular injections into the eye.

#Ophthalmology #BoehringerIngelheim #diabeticeyedisease #diabeticmacularoedema #DME #BI1815368 #THULITEstudy #centreinvolvedDME #VEGFtargetingdrugs #Roche #Vabysmo #faricimab #Lucentis #ranibizumab #Bayer #Regeneron #Eylea #aflibercept #Susvimo #ranibizumab
pharmaphorum.com/news/boehrin...

4DMT lays off 25% of workforce while accelerating phase 3 eye gene therapy timeline 4D Molecular Therapeutics

4DMT puts everything on the line for its bicistronic approach delivering aflibercept and siRNA against VEGF-C. Does this include pausing its 4D-175 asset delivering shortened FH in GA? #wetAMD #CNV #aflibercept #AAV

Patologie retiniche, Ema raccomanda aflibercept 8 mg fino a ogni 6 mesi (Adnkronos) - Nuove prospettive per i pazienti con patologie retiniche. Il Comitato per i medicinali per uso umano (Chmp) dell'Agenzia europea per i medicinali (Ema) ha espresso parere positivo per un'ulteriore estensione dell'intervall...

Patologie retiniche, Ema raccomanda aflibercept 8 mg fino a ogni 6 mesi ... LEGGI TUTTO #PatologieRetiniche #Aflibercept #Ema #Chmp #Salute

Increased intraocular inflammation after high-dose aflibercept in real-world setting Real-world data suggest a higher incidence of intraocular inflammation after intravitreal injection of aflibercept 8 mg than has been previously reported in clinical trials.

#MedNews - Real-world data suggest a higher incidence of intraocular inflammation after intravitreal injection of #aflibercept 8 mg than has been previously reported in clinical trials.

Full story 👉 buff.ly/gYjKkan

#EyeMed #MacularDegeneration